Dalriada Drug Discovery
Kelly De Freitas currently serves as the Chief Financial Officer at Dalriada Drug Discovery since June 2023. Prior to this role, Kelly held significant positions, including Chief Financial Officer and Managing Partner at EQUA Specialty Risk Partners Corporation from October 2019 to January 2023, and Finance Consultant for Canada Operations at Landmark Structures from October 2019 to May 2020. Additionally, Kelly was the Executive Finance Director Canada and CFO at Jardine Lloyd Thompson Canada Inc. from January 2017 to January 2019, as well as CFO of the Xerox Research Centre of Canada from January 2014 to January 2017. Educational qualifications include a Bachelor of Business Administration with Honors in Finance & Accounting from Brock University and a Chartered Professional Accountant designation from CPA Canada.
This person is not in any teams
This person is not in any offices
Dalriada Drug Discovery
Dalriada is a small molecule drug discovery company supporting global innovators through its TURN-KEY™ model, where R&D is perfectly aligned with business and IP. With all R&D operations in Mississauga, Canada, we build focused expert teams in MedChem, Biology and ADME to allow for the most rapid project advancements and value building. Continuing to innovate alongside start-ups and billion-dollar companies…